Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06578299 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

Name: Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer — clinical trial record (NCT06578299)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorFudan University

Started2024-08-30

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 29, 2024 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic characteristics, efficacy and safety. The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrent/metastatic breast cancer who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab in the first line, and help clinical decision-making.

Trial Details

NCT Number	NCT06578299
Lead Sponsor	Fudan University
Conditions	Breast Cancer Stage IV
Enrollment	100 participants
Start Date	2024-08-30
Primary Completion	2026-03-30 (estimated)
Study Completion	2027-08-30 (estimated)
Updated on ClinicalTrials.gov	2024-08-29